Chi Leung Chiang
The University of Hong Kong
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name Chi Leung Chiang as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-12 08:10 UTC. Open this list on ClinicalTrials.gov
- Ph2NCT04923529 · TAS-102 in Patients With Advanced, Refractory Pancreatic AdenocarcinomaThe University of Hong Kong · completed · Pancreas Cancer · principal investigator
- Ph2NCT04396886 · Bintrafusp Alfa in Previously Treated Patients With R/M Non-keratinizing NPCThe University of Hong Kong · completed · Nasopharyngeal Carcinoma, Recurrent Carcinoma, Metastatic Cancer · principal investigator
- Ph2NCT03817736 · Sequential TACE and SBRT Followed by ImmunoTherapy for Downstaging HCC for HepatectomyThe University of Hong Kong · completed · HCC · principal investigator
Grants
NIH projects from RePORTER, fetched 2026-11-12 08:10 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. 13 other NIH projects list an investigator with the same name at a different institution and are left out. Coverage is US federal funding only; UK and EU funders are not searched yet.
No NIH project could be tied to this name by a shared trial or a matching institution.
Most cited trial papers
Clinical-trial papers with this author name, ranked by citations from NIH iCite, fetched 2026-11-12 08:10 UTC. The ranking covers the 200 most relevant of 11 PubMed records, and a shared surname and initials can bring in a namesake. All 11 on PubMed
- Aerobic interval training improves oxygen uptake efficiency by enhancing cerebral and muscular hemodynamics in patients with heart failure.Int J Cardiol · 2013170 citationsRCR 6.6
- Sequential transarterial chemoembolisation and stereotactic body radiotherapy followed by immunotherapy as conversion therapy for patients with locally advanced, unresectable hepatocellular carcinoma (START-FIT): a single-arm, phase 2 trial.Lancet Gastroenterol Hepatol · 2023137 citationsRCR 12.8
- Combination atezolizumab, bevacizumab, pemetrexed and carboplatin for metastatic EGFR mutated NSCLC after TKI failure.Lung Cancer · 202167 citationsRCR 3.2
- Cost-effectiveness of Pembrolizumab as a Second-Line Therapy for Hepatocellular Carcinoma.JAMA Netw Open · 202146 citationsRCR 2.3
- Randomized Phase II Study of the X-linked Inhibitor of Apoptosis (XIAP) Antisense AEG35156 in Combination With Sorafenib in Patients With Advanced Hepatocellular Carcinoma (HCC).Am J Clin Oncol · 201644 citationsRCR 1.4
- Interferon-alpha treatment in children and young adults with chronic hepatitis B: a long-term follow-up study in Taiwan.Liver Int · 200827 citationsRCR 0.7
- Using the genomic adjusted radiation dose (GARD) to personalize the radiation dose in nasopharyngeal cancer.Radiother Oncol · 202412 citationsRCR 1.5
- Characterization of Hepatitis B Virus in Tenofovir-Treated and Untreated Chronically Infected Mothers and Their Immunoprophylaxis Failure Infants.Clin Infect Dis · 20236 citationsRCR 0.6
- A Smartphone App (WExercise) to Promote Physical Activity Among Cancer Survivors: Randomized Controlled Trial.J Med Internet Res · 20253 citationsRCR 1.5
- 1 citationsRCR 0.4